TerminatedPhase 2NCT00601926
Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Studying Papillary renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Paul Monk
- Principal Investigator
- Paul Monk, MDOhio State University
- Intervention
- bevacizumab(biological)
- Enrollment
- 5 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2013
Study locations (1)
- Ohio State University Medical Center, Columbus, Ohio, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00601926 on ClinicalTrials.govOther trials for Papillary renal cell carcinoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT05411081Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT05096390Axitinib +/- Pembrolizumab in First Line Treatment of mPRCCCentre Leon Berard
- ACTIVE NOT RECRUITINGPHASE3NCT05043090Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCAstraZeneca